EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantification of Anti‐Ro52, Anti‐Ro60 and Anti‐La Autoantibodies at High Sample Dilution and Their Predictive Value for Congenital Heart Block

Lisa Rudolph iD, Elina Richardsdotter Möller, Rui Da Silva Rodrigues iD, Gregoire Martin de Fremont iD, Vijole Ottosson, Linda Lagnefeld, Iva Gunnarsson iD, Elisabet Svenungsson iD, Felicia Nordenstam iD, Gunnar Bergman iD, Sven-Erik Sonesson iD, Gudny Ella Thorlacius und 1 weitere

Scandinavian Journal of Immunology · 2026-11 · 104 (5)

DOI: 10.1111/sji.70164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scandinavian Journal of Immunology, online erschienen am 03.11.2026. Verfasst von Lisa Rudolph und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: Heart Block, Antibodies, Antinuclear, Ribonucleoproteins, Autoantibodies. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Hjärt-Lungfonden, Stockholms Läns Landsting.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Maternal anti‐Ro/La antibodies confer a risk of congenital heart block (CHB), but current methods for predicting risk relying on the presence or absence of these autoantibodies perform poorly. To identify more accurate biomarkers of CHB risk, we investigated the association between maternal levels of autoantibodies and the risk of CHB. A total of 318 women positive for anti‐Ro/SSA autoantibodies were included. Autoantibody presence was obtained from health records for all, and ELISA was used to quantify levels of anti‐Ro52, anti‐Ro60, and anti‐La in a subset of 116 women with samples obtained during pregnancy, including 27 CHB‐affected pregnancies. Predictive models for CHB risk were developed using logistic regression and machine learning. Anti‐Ro/SSA positive women with anti‐Ro60 were more likely to have pregnancies with CHB ( p < 0.05). Levels of both anti‐Ro60 ( p < 0.001) and anti‐Ro52 ( p < 0.05) were significantly higher in CHB‐affected pregnancies and correlated ( r = 0.8, p < 0.0001), while levels of anti‐La did not differ between groups. Levels of anti‐Ro60 were identified as the strongest individual predictor of CHB, with a relative risk of 16.3 (95% CI 1.04–255.0, p < 0.001) for the top versus the bottom decile. In all tested combinations, models that included anti‐Ro60 levels outperformed models that did not. Models based on anti‐Ro60 levels alone reached an area under the curve (AUC) of 0.76 and an odds ratio (OR) per standard deviation increase of 2.8 (95% CI 1.6–5.3). These findings confirm a strong association between maternal anti‐Ro antibody levels and CHB risk in anti‐SSA‐positive pregnancy, highlighting anti‐Ro60 autoantibody levels as a valuable biomarker in risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart BlockAntibodies, AntinuclearRibonucleoproteinsAutoantibodiesAutoantigensRNA, Small CytoplasmicHumansFemalePregnancySS-A AntigenAdultBiomarkersPredictive Value of TestsSS-B Antigen

Stichwörter der Autor:innen

LaRo52Ro60autoantibodiescongenital heart block

Substanzen

Antibodies, AntinuclearSS-A AntigenRibonucleoproteinsBiomarkersSS-A antibodiesAutoantibodiesRO60 protein, humanAutoantigensSS-B AntigenRNA, Small Cytoplasmic

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.
  • Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Pediatric Cardiology Unit, Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.

ORCID-Profile: Lisa Rudolph, Rui Da Silva Rodrigues, Gregoire Martin de Fremont, Iva Gunnarsson, Elisabet Svenungsson, Felicia Nordenstam, Gunnar Bergman, Sven-Erik Sonesson, Marie Wahren-Herlenius

Förderung

  • Vetenskapsrådet
  • Hjärt-Lungfonden
  • Stockholms Läns Landsting
  • Norges Forskningsråd
  • Reumatikerförbundet
  • Knut och Alice Wallenbergs Stiftelse
  • Stiftelsen Konung Gustaf V:s 80-årsfond
  • FOREUM Foundation for Research in Rheumatology

Zitieren

APA

Rudolph, L., Möller, E. R., Rodrigues, R. D. S., de Fremont, G. M., Ottosson, V., Lagnefeld, L., Gunnarsson, I., Svenungsson, E., Nordenstam, F., Bergman, G., Sonesson, S. E., Thorlacius, G. E., & Wahren-Herlenius, M. (2026). Quantification of Anti‐Ro52, Anti‐Ro60 and Anti‐La Autoantibodies at High Sample Dilution and Their Predictive Value for Congenital Heart Block. Scandinavian Journal of Immunology, 104(5). https://doi.org/10.1111/sji.70164

Vancouver

Rudolph L, Möller ER, Rodrigues RDS, de Fremont GM, Ottosson V, Lagnefeld L, et al. Quantification of Anti‐Ro52, Anti‐Ro60 and Anti‐La Autoantibodies at High Sample Dilution and Their Predictive Value for Congenital Heart Block. Scandinavian Journal of Immunology. 2026;104(5). doi:10.1111/sji.70164

BibTeX
@article{Rudolph2026,
  author = {Rudolph, Lisa and Möller, Elina Richardsdotter and Rodrigues, Rui Da Silva and de Fremont, Gregoire Martin and Ottosson, Vijole and Lagnefeld, Linda and Gunnarsson, Iva and Svenungsson, Elisabet and Nordenstam, Felicia and Bergman, Gunnar and Sonesson, Sven-Erik and Thorlacius, Gudny Ella and Wahren-Herlenius, Marie},
  title = {Quantification of Anti‐Ro52, Anti‐Ro60 and Anti‐La Autoantibodies at High Sample Dilution and Their Predictive Value for Congenital Heart Block},
  journal = {Scandinavian Journal of Immunology},
  year = {2026},
  volume = {104},
  number = {5},
  doi = {10.1111/sji.70164}
}
Kostenlos starten →